Immunovant (IMVT) Assets Average (2019 - 2026)

Immunovant's Assets Average history runs 8 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• Quarterly Assets Average rose 67.85% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 67.85% YoY) and the FY2026 annual result came in at $866.6 million, up 20.15% from the prior year.
• Assets Average was $1.0 billion for Q1 2026 at Immunovant, up from $817.7 million in the prior quarter.
• Across five years, Assets Average topped out at $1.0 billion in Q1 2026 and bottomed at $321.6 million in Q3 2023.
• A 5-year average of $566.8 million and a median of $529.4 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average slipped 27.46% — and 2025, when it soared 74.6%.
• Immunovant's Assets Average stood at $442.2 million in 2022, then rose by 13.47% to $501.8 million in 2023, then decreased by 6.66% to $468.3 million in 2024, then surged by 74.6% to $817.7 million in 2025, then gained by 22.87% to $1.0 billion in 2026.
• Business Quant data shows IMVT's Assets Average at $1.0 billion in Q1 2026, $817.7 million in Q4 2025, and $622.2 million in Q3 2025.